Sun Pharma Advanced Research Company Limited (NSE:SPARC)
India · Delayed Price · Currency is INR 265.00
-12.57 (-4.53%)
Jul 10, 2026, 3:30 PM IST
Sun Pharma Advanced Research Company Earnings Call Transcripts
Fiscal Year 2026
-
Pipeline is now focused on oncology and immunology, with lead programs in MUC1 ADC and SCD153 advancing through clinical trials. Cost optimization and partnerships support progress, while key regulatory and financial milestones are expected over the next year.
Fiscal Year 2024
-
Portfolio is now focused on oncology and immunology, prioritizing SCD-153 and SBO-154, with flexible business models and cost controls in place. Multiple short-term cash catalysts are being pursued, including litigation, licensing, and regulatory milestones, while key clinical programs advance toward major data readouts.